Fortrea Holdings Inc
FTREHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET
20.38-1.01 (-4.72%)
2026-11-12 01:21 CET
Market cap
2,064.14 USD m
Revenue, TTM
2,666.70 USD m
Net income, TTM
-68.70 USD m
Free cash flow, TTM
169.00 USD m
EPS diluted, TTM
-0.74
P/E
-
Price
FTRE against its 20, 50 and 200-day averages2050200beat
22.1% under the 52-week high of 26.16 on 28 Oct 2026. 52-week low 8.55 on 6 Apr 2026. Last 15 sessions, 33.1% high to low
Volume 0.92× normal · the line is the 50-bar volume average
Profile
FTRE52-week range, 67% of the way up
8.5526.16
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. It operates under the Clinical Services and Enabling Services Segments. The Clinical Services segment provides services across the clinical pharmacology, clinical development, and other clinical service spectrum utilizing enabling services and technology through multiple delivery models. The Enabling Services segment provides technology solutions directly to customers that streamline complex randomization and optimize the trial drug supply process, while minimizing operational costs and supporting timely and accurate patient dosing. The company was founded on January 31, 2023 and is headquartered in Durham, NC.
| Index | RUT |
|---|---|
| Employees | 14300 |
| IPO | Jun 16, 2023 |
| Beta | 1.85 |
| ATR, 14d | 1.44 |
| Rel volume | 0.92 |
| Short float | 8.97% |
| Insider own | 1.00% |
| Inst own | 105.65% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | 1.97B |
| Enterprise Value | 2.86B |
| Income | -68.70M |
| Sales | 2.67B |
| Book/sh | 5.52 |
| Cash/sh | 2.29 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 14300 |
| IPO | Jun 16, 2023 |
Ratios
| P/E | - |
|---|---|
| Forward P/E | 19.56 |
| PEG | 0.44 |
| P/S | 0.74 |
| P/B | 3.69 |
| P/C | 8.92 |
| P/FCF | 11.64 |
| EV/EBITDA | 23.10 |
| EV/Sales | 1.07 |
| Quick Ratio | 0.97 |
| Current Ratio | 0.97 |
| Debt/Eq | 2.10 |
| LT Debt/Eq | 2.04 |
| Option/Short | Yes / Yes |
Earnings
| EPS (ttm) | -0.74 |
|---|---|
| EPS next Y | 1.04 |
| EPS next Q | 0.20 |
| EPS this Y | 98.60% |
| EPS next Y | 22.02% |
| EPS next 5Y | 44.44% |
| EPS past 3/5Y | - -21.68% |
| Sales past 3/5Y | -4.19% 1.09% |
| EPS Y/Y TTM | 93.48% |
| Sales Y/Y TTM | -3.38% |
| EPS Q/Q | 103.38% |
| Sales Q/Q | -1.40% |
| Earnings | Oct 29 BMO |
| EPS/Sales Surpr. | 28.97% 2.97% |
Ownership
| Insider Own | 1.00% |
|---|---|
| Insider Trans | -20.32% |
| Inst Own | 105.65% |
| Inst Trans | 0.38% |
| ROA | -2.51% |
| ROE | -12.34% |
| ROIC | -4.25% |
| Gross Margin | 17.05% |
| Oper. Margin | 1.70% |
| Profit Margin | -2.58% |
| SMA20 | -9.19% |
| SMA50 | -1.53% |
| SMA200 | 28.43% |
| Trades | - |
Technical
| Shs Outstand | 96.50M |
|---|---|
| Shs Float | 95.53M |
| Short Float | 8.97% |
| Short Ratio | 5.21 |
| Short Interest | 8.57M |
| 52W High | 26.16 -22.09% |
| 52W Low | 8.55 138.36% |
| Volatility | 6.49% 6.49% |
| ATR (14) | 1.44 |
| RSI (14) | 44.00 |
| Beta | 1.85 |
| Rel Volume | 0.92 |
| Avg Volume | 1.65M |
| Volume | 1,518,194 |
Performance
| Perf Week | -2.16% |
|---|---|
| Perf Month | -2.58% |
| Perf Quarter | 14.37% |
| Perf Half Y | 40.84% |
| Perf YTD | 18.14% |
| Perf Year | 72.86% |
| Perf 3Y | -27.76% |
| Perf 5Y | - |
| Perf 10Y | - |
| Recom | 2.50 |
| Target Price | 24.55 |
| Prev Close | 21.39 |
| Price | 20.38 |
| Change % | -4.72% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Today | Downgrade | MMizuho | Neutral → Underperform | $16 → $19 | -6.8% |
| Oct 15, 2026 | Upgrade | DDeutsche Bank | Hold → Buy | $25 | +22.7% |
| Oct 06, 2026 | Upgrade | BBarclays | Equal Weight → Overweight | $23 | +12.9% |
| Sep 30, 2026 | Initiated | UUBS | Neutral | $22 | +7.9% |
| Mar 09, 2026 | Upgrade | TTD Cowen | Hold → Buy | $15 | -26.4% |
| Jan 08, 2026 | Upgrade | TTruist | Hold → Buy | $22 | +7.9% |
| Jan 06, 2026 | Upgrade | EEvercore ISI | In-line → Outperform | $25 | +22.7% |
| Dec 15, 2025 | Upgrade | BBarclays | Underweight → Equal Weight | $15 | -26.4% |
| Dec 11, 2025 | Upgrade | CCitigroup | Neutral → Buy | $21 | +3.0% |
| Aug 04, 2025 | Upgrade | RRobert W. Baird | Neutral → Outperform | $9 | -55.8% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| ICLR | Icon Plc | 14.96B |
| MEDP | Medpace Holdings Inc | 18.59B |
| IQV | IQVIA Holdings Inc | 45.24B |
| TMO | Thermo Fisher Scientific Inc | 265.92B |
| CRL | Charles River Laboratories International Inc | 16.42B |
| LH | Labcorp Holdings Inc | 30.23B |
| CERT | Certara Inc | 1.79B |
| SHC | Sotera Health Co | 4.70B |
| TEM | Tempus AI Inc | 14.49B |
| DGX | Quest Diagnostics Inc | 28.46B |
Insider trading
latest 14 of 60| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Mcconnell Jill G. | Former Officer | Sep 11 '26 | Proposed Sale | 17.14 | 1,032 | 17,692 | Sep 11 03:22 PM | |
| Russell Carrie Elizabeth | Interim CAO | Sep 08 '26 | Option Exercise | 0.00 | 850 | 0 | 2,630 | Sep 10 04:08 PM |
| Russell Carrie Elizabeth | Interim CAO | Sep 09 '26 | Sale | 16.85 | 246 | 4,145 | 2,384 | Sep 10 04:08 PM |
| Morais Mark A. | Chief Operating Officer | Sep 08 '26 | Option Exercise | 0.00 | 7,157 | 0 | 84,943 | Sep 10 04:05 PM |
| Morais Mark A. | Chief Operating Officer | Sep 09 '26 | Sale | 16.85 | 3,149 | 53,061 | 81,794 | Sep 10 04:05 PM |
| Mcconnell Jill G. | Former Officer | Sep 10 '26 | Proposed Sale | 16.53 | 1,071 | 17,700 | Sep 10 03:20 PM | |
| Morais Mark A. | Officer | Sep 09 '26 | Proposed Sale | 16.85 | 3,149 | 53,049 | Sep 09 03:54 PM | |
| Mcconnell Jill G. | Former Officer | Sep 09 '26 | Proposed Sale | 16.85 | 1,051 | 17,706 | Sep 09 03:44 PM | |
| Russell Carrie Elizabeth | Officer | Sep 09 '26 | Proposed Sale | 16.85 | 246 | 4,144 | Sep 09 03:43 PM | |
| Morais Mark A. | Chief Operating Officer | Aug 18 '26 | Option Exercise | 0.00 | 11,313 | 0 | 82,678 | Aug 19 06:51 PM |
| Morais Mark A. | Chief Operating Officer | Aug 19 '26 | Sale | 18.19 | 4,892 | 88,985 | 77,786 | Aug 19 06:51 PM |
| Morais Mark A. | Officer | Aug 19 '26 | Proposed Sale | 18.19 | 4,892 | 88,975 | Aug 19 03:24 PM | |
| Mcconnell Jill G. | Officer | Aug 19 '26 | Proposed Sale | 18.19 | 4,892 | 88,975 | Aug 19 03:21 PM | |
| Thakral Anshul | Chief Executive Officer | Aug 06 '26 | Sale | 18.11 | 111,857 | 2,026,284 | 204,940 | Aug 07 04:05 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| IJR | iShares Core S&P Small-Cap ETF | AUM: 106.27B |
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 687.42B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.38B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.47B |
| VB | Vanguard Morningstar Small-Cap ETF | AUM: 79.59B |
| IWN | iShares Russell 2000 Value ETF | AUM: 14.10B |
| SPSM | State Street SPDR Portfolio S&P 600TM Small Cap ETF | AUM: 16.06B |
| XSMO | Invesco S&P SmallCap Momentum ETF | AUM: 2.74B |
| FNDA | Schwab Fundamental U.S. Small Company ETF | AUM: 8.98B |
| IJS | iShares S&P Small-Cap 600 Value ETF | AUM: 7.74B |
News
latest 14 of 200- Fortrea Beats And Raises Guidance Midpoints, But A $558 Million Backlog Reset And Softer Implied Q4 Test A Stock Already Priced For Recovery (Earnings Whispers) -10.61%
- Fortrea Reports Third Quarter 2026 Results (GlobeNewswire)
- Fortrea to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
- Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development (GlobeNewswire)
- Fortrea's Raised Outlook Faces Its First Real Test As Street Stays Below Guidance (Earnings Whispers) +5.62%
- Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials (GlobeNewswire)
- Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call (GlobeNewswire) +5.55%
- CRO consolidation keeps rolling. What does that mean for pharma? (Pharma Voice)
- Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Fortrea to Participate in September Investor Conferences (GlobeNewswire)
- Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials (GlobeNewswire)
- This Healthcare Services Stock Has 37% Upside (Barrons.com)
- Fortrea Holdings Inc (FTRE) Q2 2026 Earnings Call Highlights: Strong Revenue Guidance Amid ... (GuruFocus.com)
- Fortrea Reports Second Quarter 2026 Results (GlobeNewswire)
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-10-29 | 0.280 | 0.217 | 0.010 | 691.5 | 671.57 | 12 |
| 2026Q2 | 2026-07-29 | 0.230 | 0.180 | -0.139 | 678.2 | 647.57 | 11 |
| 2026Q1 | 2026-05-05 | 0.160 | 0.061 | -0.252 | 636.5 | 628.51 | 11 |
| 2025Q4 | 2026-02-26 | 0.090 | 0.169 | -0.350 | 660.5 | 665.22 | 11 |
| 2025Q3 | 2025-11-05 | 0.120 | 0.160 | -0.174 | 701.3 | 646.32 | 11 |
| 2025Q2 | 2025-08-06 | 0.190 | 0.076 | -4.138 | 710.3 | 631.46 | 11 |
| 2025Q1 | 2025-05-12 | 0.020 | -0.054 | -6.248 | 651.3 | 608.64 | 11 |
| 2024Q4 | 2025-03-03 | 0.180 | 0.365 | -0.722 | 697 | 703.26 | 11 |
| 2024Q3 | 2024-11-08 | 0.230 | 0.250 | -0.311 | 674.9 | 674.86 | 11 |
| 2024Q2 | 2024-08-12 | -0.030 | 0.068 | -1.289 | 662.4 | 689.08 | 11 |
| 2024Q1 | 2024-05-13 | -0.040 | 0.007 | -1.132 | 662.1 | 754.58 | 7 |
| 2023Q4 | 2024-03-11 | 0.190 | 0.232 | -0.405 | 775.4 | 779.09 | 7 |
| 2023Q3 | 2023-11-13 | 0.240 | 0.161 | -0.148 | 776.4 | 748.9 | 4 |
| 2023Q2 | 2023-08-14 | 0.520 | 0.390 | 0.319 | 793 | 771.51 | 1 |
| 2026Q4 | - | - | 0.197 | - | - | 672.85 | 12 |
| 2027Q1 | - | - | 0.202 | - | - | 667.98 | 9 |
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2023FY | 1.400 | 1.443 | -0.284 | 3,109 | 3,113 |
| 2024FY | 0.330 | 0.513 | -3.451 | 2,696 | 2,703 |
| 2025FY | 0.430 | 0.509 | -10.810 | 2,723 | 2,728 |
| 2026FY | - | 0.854 | - | - | 2,677 |
| 2027FY | - | 1.042 | - | - | 2,763 |
| 2028FY | - | 1.296 | - | - | 2,888 |
| 2029FY | - | 1.757 | - | - | 3,023 |
| 2030FY | - | 2.103 | - | - | 3,165 |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| 2026Q4 | S | 2026-11-10 | 11 | 1 | 2 | 672.85 | 659 | 682 |
| 2026Q4 | S | 2026-11-06 | 10 | 1 | 1 | 674.24 | 668.8 | 682 |
| 2026Q4 | S | 2026-10-30 | 11 | 1 | 1 | 674.46 | 668.8 | 682 |
| 2026Q4 | S | 2026-10-29 | 11 | 1 | 1 | 674.49 | 668.8 | 682.3 |
| 2026Q4 | S | 2026-10-28 | 11 | 1 | 0 | 676.62 | 670.41 | 682.3 |
| 2026Q4 | S | 2026-10-20 | 11 | 1 | 0 | 676.62 | 670.41 | 682.3 |
| 2026Q4 | S | 2026-10-19 | 11 | 1 | 0 | 676.62 | 670.41 | 682.3 |
| 2026Q4 | S | 2026-10-17 | 11 | 1 | 0 | 676.68 | 670.41 | 682.3 |
| 2026Q4 | S | 2026-10-13 | 11 | 2 | 0 | 676.68 | 670.41 | 682.3 |
| 2026Q4 | S | 2026-10-12 | 11 | 3 | 0 | 676.68 | 670.41 | 682.3 |
| 2026Q4 | S | 2026-10-02 | 11 | 7 | 0 | 676.68 | 670.41 | 682.3 |
| 2026Q4 | S | 2026-09-29 | 11 | 6 | 0 | 675.68 | 666.3 | 682.3 |
| 2026Q4 | S | 2026-09-28 | 10 | 6 | 0 | 675.64 | 666.3 | 682.3 |
| 2026Q4 | S | 2026-08-03 | 10 | 6 | 0 | 675.6 | 666.3 | 682.3 |
Estimate history
| EPS, annual | -4.054 | 1.106 | 2.177 | -0.284 | -3.451 | -10.814 | -0.7357 | ||
|---|---|---|---|---|---|---|---|---|---|
| Period | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
| EPS, quarterly | -0.311 | -0.722 | -6.248 | -4.138 | -0.174 | -0.35 | -0.252 | -0.139 | 0.006 |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
| Sales, annual | 2580.3 | 3057.5 | 3096.1 | 2842.5 | 2696.4 | 2723.4 | 2666.7 | ||
| Period | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
| Sales, quarterly | 674.9 | 697 | 651.3 | 710.3 | 701.3 | 660.5 | 636.5 | 678.2 | 691.5 |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
| Shares, annual | 88.6 | 88.6 | 88.6 | 88.8 | 89.7 | 93.1 | 96.5 | ||
| Period | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | MRQ | ||
| Shares, quarterly | 89.7 | 89.7 | 90.5 | 90.8 | 92.2 | 93.1 | 94.6 | 95.1 | 96.5 |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY |
|---|---|---|---|---|---|---|---|
| Total Revenue | 2,666.70 | 2,723.40 | 2,696.40 | 2,842.50 | 3,096.10 | 3,057.50 | 2,580.30 |
| Cost of Goods Sold Incl. D&A | 2,212.00 | 2,297.60 | 2,247.50 | 2,341.20 | 2,540.10 | 2,619.40 | 2,210.20 |
| Gross Profit | 454.70 | 425.80 | 448.90 | 501.30 | 556.00 | 438.10 | 370.10 |
| Selling, General and Administrative Excl. Other | 409.40 | 456.40 | 560.70 | 448.10 | 279.80 | 303.10 | 267.60 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | 45.30 | -30.60 | -111.80 | 53.20 | 276.20 | 135.00 | 102.50 |
| Interest Expense | 82.00 | 91.30 | 122.30 | 69.30 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 33.90 | 841.10 | 52.10 | 22.00 | 40.30 | 20.70 | 416.70 |
| Net Income Before Taxes | -52.70 | -983.00 | -275.00 | -30.50 | 237.00 | 136.40 | -332.20 |
| Income Taxes | 16.00 | 3.20 | -3.50 | 1.20 | 44.10 | 38.40 | 27.00 |
| Consolidated Net Income | -68.70 | -986.20 | -271.50 | -31.70 | 192.90 | 98.00 | -359.20 |
| Net Income From Continuing Operations | -68.70 | -986.20 | -271.50 | -31.70 | 192.90 | 98.00 | -359.20 |
| Net Income | -68.70 | -986.20 | -308.90 | -25.20 | 192.90 | 98.00 | -359.20 |
| EPS (Recurring) | -0.44 | -4.36 | -3.04 | -0.11 | 2.50 | 1.27 | -0.76 |
| EPS (Basic, Before Extraordinaries) | -0.74 | -10.81 | -3.45 | -0.28 | 2.18 | 1.11 | -4.05 |
| EPS (Diluted) | -0.74 | -10.81 | -3.45 | -0.28 | 2.18 | 1.11 | -4.05 |
| EBITDA | 124.00 | 47.40 | -26.50 | 142.50 | 393.80 | 333.80 | 258.90 |
| Non-Operating Income (Expense) | 17.90 | -20.00 | 11.20 | 7.60 | 1.10 | 22.10 | -18.00 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 42.19 | 63.40 | 48.10 | 33.20 | 15.70 | 21.00 | 20.20 |
| Price To Sales Ratio | 0.76 | 0.58 | 0.62 | 1.09 | - | - | - |
| Gross Margin | 17.05 | 15.63 | 16.65 | 17.64 | 17.96 | 14.33 | 14.34 |
| Operating Margin | 1.70 | -1.12 | -4.15 | 1.87 | 8.92 | 4.42 | 3.97 |
| Net Margin | -2.58 | -36.21 | -11.46 | -0.89 | 6.23 | 3.21 | -13.92 |
| Shares Outstanding | 96.50 | 93.10 | 89.70 | 88.80 | 88.60 | 88.60 | 88.60 |
| Market Capitalization | 2,064.14 | 2,064.14 | 1,672.90 | 3,099.12 | 3,099.12 | - | - |
Income statement, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 691.50 | 678.20 | 636.50 | 660.50 | 701.30 | 710.30 | 651.30 | 697.00 |
| Cost of Goods Sold Incl. D&A | 572.00 | 558.60 | 532.70 | 548.70 | 598.20 | 596.40 | 554.30 | 576.90 |
| Gross Profit | 119.50 | 119.60 | 103.80 | 111.80 | 103.10 | 113.90 | 97.00 | 120.10 |
| Selling, General and Administrative Excl. Other | 103.80 | 102.10 | 100.50 | 103.00 | 106.80 | 124.80 | 121.80 | 148.10 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | 15.70 | 17.50 | 3.30 | 8.80 | -3.70 | -10.90 | -24.80 | -28.00 |
| Interest Expense | 20.40 | 19.50 | 18.90 | 23.20 | 22.60 | 23.20 | 22.30 | 21.60 |
| Unusual Expense | 0.00 | 4.00 | 6.10 | 23.80 | 3.60 | 318.80 | 494.90 | 30.20 |
| Net Income Before Taxes | -3.60 | -1.20 | -12.30 | -35.60 | -28.70 | -370.70 | -548.00 | -74.90 |
| Income Taxes | -4.20 | 12.00 | 11.30 | -3.10 | -12.80 | 4.20 | 14.90 | -1.00 |
| Consolidated Net Income | 0.60 | -13.20 | -23.60 | -32.50 | -15.90 | -374.90 | -562.90 | -73.90 |
| Net Income From Continuing Operations | 0.60 | -13.20 | -23.60 | -32.50 | -15.90 | -374.90 | -562.90 | -73.90 |
| Net Income | 0.60 | -13.20 | -23.60 | -32.50 | -15.90 | -374.90 | -562.90 | -64.80 |
| EPS (Recurring) | 0.01 | -0.11 | -0.21 | -0.17 | -0.15 | -1.67 | -2.40 | -0.49 |
| EPS (Basic, Before Extraordinaries) | 0.01 | -0.14 | -0.25 | -0.35 | -0.17 | -4.14 | -6.25 | -0.72 |
| EPS (Diluted) | 0.01 | -0.14 | -0.25 | -0.35 | -0.17 | -4.14 | -6.25 | -0.72 |
| EBITDA | 35.70 | 37.10 | 23.10 | 28.10 | 15.90 | 8.70 | -2.10 | -7.20 |
| Non-Operating Income (Expense) | 1.10 | 4.80 | 9.40 | 2.60 | 1.20 | -17.80 | -6.00 | 4.90 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 10.40 | 10.60 | 9.50 | 11.69 | 19.20 | 19.60 | 12.30 | 12.09 |
| Price To Sales Ratio | 0.76 | 0.62 | 0.33 | 0.59 | 0.28 | 0.16 | 0.25 | 0.62 |
| Gross Margin | 17.28 | 17.63 | 16.31 | 16.93 | 14.70 | 16.04 | 14.89 | 17.23 |
| Operating Margin | 2.27 | 2.58 | 0.52 | 1.33 | -0.53 | -1.53 | -3.81 | -4.02 |
| Net Margin | 0.09 | -1.95 | -3.71 | -4.92 | -2.27 | -52.78 | -86.43 | -9.30 |
| Shares Outstanding | 96.50 | 95.10 | 94.60 | 93.10 | 92.20 | 90.80 | 90.50 | 89.70 |
| Market Capitalization | 2,064.14 | 1,646.04 | 880.77 | 1,593.90 | 764.54 | 447.07 | 681.01 | 1,672.90 |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 174.60 | 118.50 | 108.60 | 112.00 | 94.60 | - |
| Short Term Receivables | 620.00 | 694.00 | 1,010.50 | 1,022.20 | 927.00 | - |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Other Current Assets | 102.60 | 135.70 | 131.70 | 112.70 | 95.90 | - |
| Total Current Assets | 897.20 | 948.20 | 1,250.80 | 1,246.90 | 1,117.50 | - |
| Net Property, Plant & Equipment | 149.50 | 156.30 | 172.60 | 164.90 | 162.60 | - |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Intangible Assets | 1,582.00 | 2,366.10 | 2,467.50 | 2,820.60 | 3,016.40 | - |
| Deferred Tax Assets | 6.20 | 5.20 | 3.20 | 1.20 | 1.40 | - |
| Other Assets | 80.80 | 103.40 | 438.50 | 54.30 | 70.80 | - |
| Total Assets | 2,715.70 | 3,579.20 | 4,332.60 | 4,287.90 | 4,368.70 | - |
| Short Term Debt Incl. Current Port. of LT Debt | 14.00 | 88.20 | 43.30 | 23.30 | 24.00 | - |
| Accounts Payable | 29.70 | 138.20 | 132.90 | 81.50 | 60.50 | - |
| Income Tax Payable | 59.00 | 52.70 | 60.00 | 39.50 | 40.50 | - |
| Other Current Liabilities | 810.60 | 670.40 | 542.20 | 554.70 | 701.70 | - |
| Total Current Liabilities | 913.30 | 949.50 | 778.40 | 699.00 | 826.70 | - |
| Long Term Debt | 1,102.00 | 1,110.30 | 1,628.70 | 40.10 | 53.20 | - |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Deferred Tax Liabilities | 97.60 | 121.70 | 147.70 | 184.50 | 210.30 | - |
| Other Liabilities | 39.30 | 35.30 | 63.70 | 21.70 | 17.90 | - |
| Total Liabilities | 2,152.20 | 2,216.80 | 2,618.50 | 945.30 | 1,108.10 | - |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Common Equity | 563.50 | 1,362.40 | 1,714.10 | 3,342.60 | 3,260.60 | - |
| Total Shareholders Equity | 563.50 | 1,362.40 | 1,714.10 | 3,342.60 | 3,260.60 | - |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Total Equity | 563.50 | 1,362.40 | 1,714.10 | 3,342.60 | 3,260.60 | - |
| Total Liabilities & Stockholders Equity | 2,715.70 | 3,579.20 | 4,332.60 | 4,287.90 | 4,368.70 | - |
| Book Value Per Share | 6.05 | 15.19 | 19.30 | 37.73 | 36.80 | - |
| Tangible Book Value Per Share | -10.94 | -11.19 | -8.48 | 5.89 | 2.76 | - |
| Full-Time Employees | 14,300 | 15,500 | 18,000 | 19,000 | - | - |
| Price to Book Ratio | 3.88 | 1.11 | 1.83 | 1.83 | - | - |
| Return on Assets | -31.33 | -6.84 | -0.74 | 4.46 | - | - |
| Return on Equity | -102.41 | -17.51 | -1.25 | 5.84 | - | - |
| Return on Invested Capital | -59.21 | -12.49 | -0.75 | 5.70 | 2.96 | - |
| Quick Ratio | 0.98 | 1.00 | 1.61 | 1.78 | 1.35 | - |
| Current Ratio | 0.98 | 1.00 | 1.61 | 1.78 | 1.35 | - |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY |
|---|---|---|---|---|---|---|---|
| Net Income | -68.70 | -986.20 | -328.50 | -25.20 | 192.90 | 98.00 | -359.20 |
| Depreciation | 78.70 | 78.00 | 85.30 | 89.30 | 117.60 | 198.80 | 156.40 |
| Other Funds (Non Cash) | 52.90 | 939.00 | 166.10 | 119.00 | 39.30 | 30.40 | 435.10 |
| Funds from Operations | 56.30 | -1.20 | -101.70 | 141.50 | 333.30 | 297.00 | 192.00 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 145.50 | 114.70 | 364.50 | 26.90 | -245.80 | -127.20 | 8.90 |
| Cash from Operating Activities | 201.80 | 113.50 | 262.80 | 168.40 | 87.50 | 169.80 | 200.90 |
| Capital Expenditures | -32.80 | -25.20 | -25.50 | -40.30 | -54.40 | -26.50 | -24.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -137.50 |
| Sale of Fixed Assets and Businesses | 2.00 | 39.60 | 277.10 | 8.50 | 0.40 | 0.30 | 0.30 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -30.80 | 14.40 | 251.60 | -31.80 | -54.00 | -26.20 | -161.20 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Proceedsfrom Stock Options | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | -75.70 | -76.30 | -483.40 | 1,589.60 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | -75.70 | -76.30 | -483.40 | 1,589.60 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 453.30 | 825.80 | 1,769.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -75.70 | -529.60 | -1,309.20 | -179.40 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | -14.40 | -1,730.40 | -8.70 | -128.50 | -33.10 |
| Other Financing Activities Uses | 0.00 | 0.00 | -14.40 | -1,730.40 | -8.70 | -128.50 | -33.10 |
| Cash from Financing Activities | -75.70 | -76.30 | -497.80 | -140.80 | -8.70 | -128.50 | -33.10 |
| Exchange Rate Effect | -6.00 | 4.50 | -6.70 | 2.40 | -7.40 | -0.80 | 0.50 |
| Net Change in Cash | 89.30 | 56.10 | 9.90 | -1.80 | 17.40 | 14.30 | 7.10 |
| Free Cash Flow | 169.00 | 88.30 | 237.30 | 128.10 | 33.10 | 143.30 | 176.90 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price to Free Cash Flow | 11.95 | 17.82 | 7.03 | 24.19 | - | - | - |
| Deferred Taxes & Investment Tax Credit | - | -32.00 | -24.60 | -41.60 | -16.50 | -30.20 | -40.30 |
Balance sheet, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 220.60 | 168.60 | 147.50 | 174.60 | 131.30 | 81.20 |
| Short Term Receivables | 641.10 | 654.40 | 619.60 | 620.00 | 663.20 | 739.20 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 91.00 | 100.60 | 114.40 | 102.60 | 124.00 | 139.60 |
| Total Current Assets | 952.70 | 923.60 | 881.50 | 897.20 | 918.50 | 960.00 |
| Net Property, Plant & Equipment | 158.60 | 156.20 | 157.10 | 149.50 | 147.60 | 148.70 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 1,521.90 | 1,537.10 | 1,552.50 | 1,582.00 | 1,593.50 | 1,619.50 |
| Deferred Tax Assets | 6.20 | 6.20 | 6.20 | 6.20 | 8.30 | 5.60 |
| Other Assets | 98.80 | 91.80 | 86.10 | 80.80 | 74.20 | 101.30 |
| Total Assets | 2,738.20 | 2,714.90 | 2,683.40 | 2,715.70 | 2,742.10 | 2,835.10 |
| Short Term Debt Incl. Current Port. of LT Debt | 32.70 | 26.00 | 19.70 | 14.00 | 83.70 | 87.20 |
| Accounts Payable | 53.00 | 54.20 | 70.80 | 29.70 | 49.50 | 92.60 |
| Income Tax Payable | - | - | - | 59.00 | - | - |
| Other Current Liabilities | 897.60 | 883.50 | 838.60 | 810.60 | 781.20 | 762.50 |
| Total Current Liabilities | 983.30 | 963.70 | 929.10 | 913.30 | 914.40 | 942.30 |
| Long Term Debt | 1,085.70 | 1,091.50 | 1,098.30 | 1,102.00 | 1,103.60 | 1,153.80 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 97.10 | 97.00 | 92.30 | 97.60 | 106.90 | 112.80 |
| Other Liabilities | 39.80 | 38.50 | 37.80 | 39.30 | 36.40 | 37.00 |
| Total Liabilities | 2,205.90 | 2,190.70 | 2,157.50 | 2,152.20 | 2,161.30 | 2,245.90 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 532.30 | 524.20 | 525.90 | 563.50 | 580.80 | 589.20 |
| Total Shareholders Equity | 532.30 | 524.20 | 525.90 | 563.50 | 580.80 | 589.20 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 532.30 | 524.20 | 525.90 | 563.50 | 580.80 | 589.20 |
| Total Liabilities & Stockholders Equity | 2,738.20 | 2,714.90 | 2,683.40 | 2,715.70 | 2,742.10 | 2,835.10 |
| Book Value Per Share | 5.52 | 5.51 | 5.56 | 6.05 | 6.30 | 6.49 |
| Tangible Book Value Per Share | -10.25 | -10.65 | -10.85 | -10.94 | -10.98 | -11.35 |
| Full-Time Employees | - | - | - | 14,300 | - | - |
| Price to Book Ratio | 3.88 | 3.13 | 1.56 | 2.74 | 1.30 | 0.52 |
| Return on Assets | -2.51 | -3.07 | -15.40 | -31.33 | -32.08 | -32.19 |
| Return on Equity | -12.34 | -15.30 | -64.55 | -102.41 | -98.13 | -100.49 |
| Return on Invested Capital | 0.04 | -0.82 | -1.45 | -1.95 | -0.94 | -21.51 |
| Quick Ratio | 0.97 | 0.96 | 0.95 | 0.98 | 1.00 | 1.02 |
| Current Ratio | 0.97 | 0.96 | 0.95 | 0.98 | 1.00 | 1.02 |
Cash flow, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 |
|---|---|---|---|---|---|---|
| Net Income | 0.60 | -13.20 | -23.60 | -32.50 | -15.90 | -374.90 |
| Depreciation | 20.00 | 19.60 | 19.80 | 19.30 | 19.60 | 16.40 |
| Other Funds (Non Cash) | 9.90 | 17.30 | 8.60 | 17.10 | 30.50 | 380.20 |
| Funds from Operations | 30.60 | 28.60 | 0.80 | -3.70 | 26.60 | 11.50 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 30.20 | 0.30 | -17.80 | 132.80 | 60.20 | 10.30 |
| Cash from Operating Activities | 60.80 | 28.90 | -17.00 | 129.10 | 86.80 | 21.80 |
| Capital Expenditures | -8.30 | -9.00 | -8.00 | -7.50 | -7.30 | -7.50 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 2.00 | 0.00 | 0.00 | 20.60 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -8.30 | -7.00 | -8.00 | -7.50 | 13.30 | -7.50 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Proceedsfrom Stock Options | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | -75.70 | -50.00 | -39.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | -75.70 | -50.00 | -39.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 137.50 | 149.90 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | -75.70 | -187.50 | -188.90 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 0.00 | 0.00 | 0.00 | -75.70 | -50.00 | -39.00 |
| Exchange Rate Effect | -0.50 | -0.80 | -2.10 | -2.60 | 0.00 | 4.30 |
| Net Change in Cash | 52.00 | 21.10 | -27.10 | 43.30 | 50.10 | -20.40 |
| Free Cash Flow | 52.50 | 19.90 | -25.00 | 121.60 | 79.50 | 14.30 |
| Price to Free Cash Flow | 11.95 | 8.42 | 4.63 | 18.13 | - | - |
Revenue breakdown
| Europe | 2024: 800.00M 2025: 851.70M |
|---|---|
| North America | 2024: 1.27B 2025: 1.29B |
| Other Geographical Areas | 2024: 626.90M 2025: 582.10M |
| Total Services-Medical Laboratories revenue | 2024: 2.70B 2025: 2.72B |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 8.97% | 8.6M | 95.5M | 1.66M |
| 2026-10-15 | 8.15% | 7.7M | 94.2M | 1.55M |
| 2026-09-30 | 13.35% | 12.6M | 94.2M | 1.41M |
| 2026-09-15 | 13.33% | 12.6M | 94.1M | 1.44M |
| 2026-08-31 | 12.68% | 11.9M | 94.1M | 1.45M |
| 2026-08-14 | 12.22% | 11.5M | 94.1M | 1.47M |
| 2026-07-31 | 11.87% | 11.2M | 94.0M | 1.48M |
| 2026-07-15 | 10.93% | 10.3M | 93.9M | 1.43M |
| 2026-06-30 | 10.41% | 9.8M | 93.9M | 1.41M |
| 2026-06-15 | 10.51% | 9.9M | 93.9M | 1.32M |
| 2026-05-29 | 10.08% | 9.5M | 94.0M | 1.41M |
| 2026-05-15 | 10.10% | 9.5M | 93.9M | 1.55M |
| 2026-04-30 | 11.23% | 10.6M | 94.0M | 1.64M |
| 2026-04-15 | 11.38% | 10.6M | 93.0M | 1.57M |
| 2026-03-31 | 11.09% | 10.3M | 93.0M | 1.67M |
| 2026-03-13 | 11.58% | 10.8M | 93.0M | 1.66M |
| 2026-02-27 | 10.22% | 9.5M | 93.0M | 1.58M |
| 2026-02-13 | 9.78% | 9.0M | 91.9M | 1.46M |
| 2026-01-30 | 10.03% | 9.2M | 91.9M | 1.35M |
| 2026-01-15 | 9.61% | 8.8M | 91.9M | 1.35M |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 2.50 | 17.30 | 20.10 | 12.56 | 25.965 | 1.00 | 0.00 | 0.995 | -0.018 | 0.000 |
| call | 5.00 | 14.80 | 17.60 | 0.00 | 12.980 | 0.00 | 0.00 | 0.963 | -0.111 | 0.003 |
| call | 7.50 | 12.30 | 15.10 | 12.54 | 9.239 | 1.00 | 0.00 | 0.945 | -0.111 | 0.004 |
| call | 10.00 | 9.50 | 12.60 | 10.20 | 7.003 | 7.00 | 0.00 | 0.924 | -0.107 | 0.005 |
| call | 12.50 | 7.00 | 10.10 | 9.89 | 5.388 | 7.00 | 0.00 | 0.896 | -0.101 | 0.006 |
| call | 15.00 | 4.90 | 7.60 | 5.50 | 4.095 | 50.00 | 0.00 | 0.857 | -0.090 | 0.007 |
| call | 17.50 | 2.35 | 5.10 | 7.23 | 2.977 | 74.00 | 0.00 | 0.789 | -0.075 | 0.009 |
| call | 20.00 | 1.00 | 1.35 | 1.40 | 0.910 | 1,326 | 42.00 | 0.584 | -0.063 | 0.012 |
| call | 22.50 | 0.00 | 0.55 | 4.60 | 1.015 | 506 | 0.00 | 0.294 | -0.063 | 0.011 |
| call | 25.00 | 0.00 | 0.75 | 0.40 | 1.495 | 1,454 | 0.00 | 0.224 | -0.081 | 0.009 |
| call | 27.50 | 0.00 | 0.75 | 0.25 | 1.880 | 94.00 | 0.00 | 0.191 | -0.092 | 0.009 |
| call | 30.00 | 0.00 | 0.75 | 0.10 | 2.206 | 1,258 | 0.00 | 0.171 | -0.101 | 0.008 |
| call | 32.50 | 0.00 | 1.95 | 0.00 | 2.491 | 0.00 | 0.00 | 0.157 | -0.108 | 0.008 |
| call | 35.00 | 0.00 | 0.75 | 0.00 | 2.743 | 0.00 | 0.00 | 0.147 | -0.113 | 0.007 |
| call | 37.50 | 0.00 | 0.75 | 0.00 | 2.971 | 0.00 | 0.00 | 0.139 | -0.118 | 0.007 |
| put | 2.50 | 0.00 | 0.05 | 0.00 | 6.374 | 0.00 | 0.00 | -0.005 | -0.016 | 0.001 |
| put | 5.00 | 0.00 | 0.75 | 0.00 | 7.565 | 0.00 | 0.00 | -0.037 | -0.110 | 0.003 |
| put | 7.50 | 0.00 | 0.75 | 0.18 | 5.516 | 3.00 | 0.00 | -0.055 | -0.110 | 0.004 |
| put | 10.00 | 0.00 | 0.75 | 1.15 | 4.137 | 122 | 0.00 | -0.076 | -0.106 | 0.005 |
| put | 12.50 | 0.00 | 0.75 | 0.11 | 3.081 | 14.00 | 0.00 | -0.104 | -0.099 | 0.006 |
| put | 15.00 | 0.00 | 0.95 | 0.30 | 2.204 | 19.00 | 0.00 | -0.143 | -0.089 | 0.007 |
| put | 17.50 | 0.00 | 2.00 | 0.01 | 1.420 | 122 | 0.00 | -0.211 | -0.073 | 0.009 |
| put | 20.00 | 0.55 | 1.85 | 0.38 | 0.870 | 170 | 0.00 | -0.416 | -0.061 | 0.012 |
| put | 22.50 | 0.55 | 3.60 | 1.53 | 1.817 | 133 | 0.00 | -0.706 | -0.061 | 0.011 |
| put | 25.00 | 3.30 | 5.60 | 2.23 | 1.935 | 1.00 | 0.00 | -0.776 | -0.078 | 0.009 |
| put | 27.50 | 5.70 | 8.00 | 0.00 | 2.260 | 0.00 | 0.00 | -0.809 | -0.089 | 0.009 |
| put | 30.00 | 8.00 | 10.60 | 5.26 | 2.715 | 0.00 | 0.00 | -0.829 | -0.097 | 0.008 |
| put | 32.50 | 10.30 | 12.70 | 0.00 | 2.570 | 0.00 | 0.00 | -0.843 | -0.104 | 0.008 |
| put | 35.00 | 12.80 | 15.20 | 0.00 | 2.830 | 0.00 | 0.00 | -0.853 | -0.109 | 0.007 |
| put | 37.50 | 15.30 | 17.70 | 0.00 | 3.063 | 0.00 | 0.00 | -0.861 | -0.114 | 0.007 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-10-29 | 8-K | Current report | 2026-10-29 | SEC |
| 2026-10-29 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-09-30 | 8-K | Current report | 2026-09-29 | SEC |
| 2026-09-14 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-10 | SEC |
| 2026-09-11 | 144/A | SEC | ||
| 2026-09-11 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-08 | SEC |
| 2026-09-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-08 | SEC |
| 2026-09-10 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-10 | 8-K | Current report | 2026-09-09 | SEC |
| 2026-09-09 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-09 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-09 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-19 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-18 | SEC |
| 2026-08-19 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-19 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-17 | 3 | Initial statement of beneficial ownership of securities | 2026-08-07 | SEC |
| 2026-08-07 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-06 | SEC |
| 2026-08-06 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-04 | SEC |
| 2026-08-06 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-03 | SEC |
| 2026-08-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-03 | SEC |
| 2026-08-05 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-03 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-07-29 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-07-29 | 8-K | Current report | 2026-07-27 | SEC |
| 2026-07-27 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-20 | SEC |
| 2026-07-15 | 3 | Initial statement of beneficial ownership of securities | 2026-07-06 | SEC |
| 2026-07-14 | 8-K | Current report | 2026-07-08 | SEC |
| 2026-06-26 | 8-K | Current report | 2026-06-26 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 57.21K | 2 |
| 2026-08 | 0 | 0 | 4.20M | 4 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 229.37K | 3 |
| 2026-05 | 0 | 0 | 26.88K | 1 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 138.36K | 5 |
| 2026-02 | 0 | 0 | 28.59K | 2 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| BlackRock, Inc. | 16.70% |
| GOLDMAN SACHS GROUP INC | 8.89% |
| Sessa Capital IM, L.P. | 4.86% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.42% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.03% |
| FMR LLC | 4.00% |
| STATE STREET CORP | 4.00% |
| Corvex Management LP | 3.16% |
| AQR CAPITAL MANAGEMENT LLC | 3.15% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.63% |
Funds
| Fund | % owned |
|---|---|
| Lord Abbett Short Duration High Yield Fund | 34.50% |
| iShares Broad USD High Yield Corporate Bond ETF | 11.30% |
| Eaton Vance Income Fund of Boston | 11.16% |
| BlackRock High Yield Portfolio | 9.74% |
| NYLI MacKay High Yield Corporate Bond Fund | 6.17% |
| iShares High Yield Systematic Bond ETF | 6.12% |
| iShares Core S&P Small-Cap ETF | 6.03% |
| MFS High Income Fund | 5.52% |
| State Street(R) SPDR(R) Portfolio High Yield Bond ETF | 5.19% |
| Lord Abbett High Yield Fund | 4.96% |
OakChart. FTRE. Cached 15 minutes.